Ashland Inc. — Q1 FY2024 Form 10-Q
Reporting period: Three months ended December 31, 2023. Ashland is a global specialty ingredients and additives company. Amounts below are in U.S. dollars; financial statement figures are in millions unless noted.
Financial performance
| Metric | Q1 FY2024 | Q1 FY2023 |
|---|---|---|
| Sales | $473 | $525 |
| Gross profit / gross margin | $98 / 20.7% | $165 / 31.4% |
| Operating income (loss) | $(18) | $37 |
| Income from continuing operations | $28 | $42 |
| Net income | $26 | $40 |
| Diluted EPS | $0.51 | $0.73 |
| Adjusted EBITDA (non-GAAP) | $70 | $108 |
| Adjusted diluted EPS excluding amortization (non-GAAP) | $0.45 | $0.97 |
Sales declined $52 million, primarily from lower volumes ($51 million); pricing reduced sales by $6 million, partly offset by $6 million of favorable foreign exchange. Gross margin contracted 10.7 percentage points. Management attributed the pressure to lower volume and higher unit manufacturing costs, including $21 million of accelerated depreciation tied to Specialty Additives product-line optimization.
Income before taxes was $4 million, compared with $50 million a year earlier. A $24 million income tax benefit, primarily from favorable discrete items related to foreign tax reform, contributed to continuing-operations income of $28 million; the reported effective tax rate was a benefit of 600%. The filing reports adjusted measures as non-GAAP and provides reconciliations.
Segments and material changes
- Life Sciences: Sales $200 million, down $7 million; operating income $32 million, down $2 million; adjusted EBITDA $48 million versus $52 million.
- Personal Care: Sales $129 million, down $9 million; operating income $2 million, down $9 million; EBITDA $22 million versus $32 million.
- Specialty Additives: Sales $122 million, down $21 million; operating loss $32 million versus income of $1 million. Adjusted EBITDA was $6 million versus $23 million; results included $21 million of accelerated depreciation.
- Intermediates: Sales $33 million, down $21 million; operating income $7 million versus $20 million; EBITDA $10 million versus $23 million.
Across the segments, lower volume was a key headwind. Management also cited higher costs in Life Sciences, Personal Care and Specialty Additives, and lower volume, unfavorable price/mix and higher costs in Intermediates. Improved price versus raw-material costs and lower SG&A partially offset the consolidated decline.
Cash flow, debt and liquidity
- Cash from continuing operating activities was $201 million, versus cash used of $29 million. Capital expenditures were $36 million versus $23 million; reported free cash flow was $165 million versus negative $52 million.
- Ongoing free cash flow, a non-GAAP measure incorporating specified adjustments, was $66 million versus negative $21 million. The filing cites lower inventory and reduced incentive compensation payments as contributors, offset partly by higher capital expenditures.
- Cash and cash equivalents were $440 million at December 31, 2023, up from $417 million at September 30, 2023. The quarter included $100 million of share repurchases and $20 million of dividends.
- Debt was $1.341 billion, compared with $1.330 billion at September 30, 2023. No current debt was reported; $554 million of scheduled principal maturities fall in 2028. Debt was 31% of capital employed.
- Available liquidity from cash and the revolving credit facility was $1.036 billion, including $596 million of undrawn capacity. Restricted investments of $392 million are designated for asbestos and environmental obligations and are not the same as unrestricted cash.
- Ashland reported compliance with debt covenants. Its net leverage ratio was 2.1 against a maximum of 4.0; interest coverage was 7.6 against a minimum of 3.0.
Outlook, risks and unusual items
Management said demand showed sequential improvement in January, with similar trends in February order build, and saw potential for recovery and momentum into the second half of the fiscal year. It expected a partial return to more typical margins in Q2, primarily from forecast higher sales and production volumes, with further improvement during the year.
Guidance was sales of $565 million–$585 million and adjusted EBITDA of $115 million–$125 million for fiscal Q2; full-year fiscal 2024 sales of $2.15 billion–$2.25 billion and adjusted EBITDA of $460 million–$500 million. These are management’s non-GAAP outlook measures; the filing says it is not providing a reconciliation to forward-looking GAAP measures because certain significant items cannot be predicted with reasonable certainty.
- Portfolio optimization is expected, when completed, to improve adjusted EBITDA margins by approximately 200–250 basis points and returns on net assets by 150–200 basis points. Actions include consolidating CMC production at Alizay, France, with closure of Hopewell, Virginia capacity planned during fiscal Q2; other MC and HEC actions were still being assessed.
- Gross asbestos claim reserves were $271 million for Ashland-related claims and $186 million for Hercules-related claims. The filing says modeled future costs could be as high as approximately $422 million and $288 million, respectively, depending on assumptions. Related probable insurance receivables were $93 million and $46 million. Estimates depend on uncertain claim volumes, severity, litigation outcomes, costs and insurer solvency.
- Environmental remediation reserves were $207 million, with $16 million of recorded probable insurance recoveries. The estimated upper end of the reasonably possible future cost range for identified sites was approximately $455 million. Ashland reported 55 potentially responsible party sites and 14 actively remediated service station properties.
- The quarter included $5 million of Argentina currency devaluation impact, $4 million of restructuring and other costs, and a $1 million lease-asset impairment; these were among items excluded in adjusted measures. Restricted-investment gains also affected reported results: income from restricted investments was $36 million, including $31 million of realized gains.
- Management highlighted macroeconomic, raw-material, foreign-exchange, geopolitical, supply-chain, competitive, legal, environmental and asbestos-related uncertainties. Sales to Ukraine, Russia and Belarus were less than 1% of consolidated sales; sales to Israel were approximately 1%. The company reported no manufacturing operations in those countries.
Important facts for investors to verify
- Whether the expected demand recovery, margin improvement and Q2/full-year adjusted EBITDA guidance are realized.
- Whether portfolio optimization delivers the projected margin and return improvements, and what costs or operating disruptions accompany the actions.
- How much of operating cash flow and ongoing free cash flow reflects sustainable operations versus working-capital movements and receivables sales programs.
- Whether asbestos and environmental reserve assumptions, insurance recoveries and ultimate cash payments remain consistent with current estimates.
- The effect of lower segment volumes, manufacturing costs, restricted-investment gains and the unusually large discrete tax benefit on comparable underlying earnings.